Lee, Eunjung http://orcid.org/0000-0002-6476-9527
Ito, Saki
Miranda, William R.
Lopez-Jimenez, Francisco
Kane, Garvan C.
Asirvatham, Samuel J.
Noseworthy, Peter A.
Friedman, Paul A. http://orcid.org/0000-0001-5052-2948
Carter, Rickey E. http://orcid.org/0000-0002-0818-273X
Borlaug, Barry A. http://orcid.org/0000-0001-9375-0596
Attia, Zachi I. http://orcid.org/0000-0002-9706-7900
Oh, Jae K. http://orcid.org/0000-0002-8303-5780
Article History
Received: 10 July 2023
Accepted: 11 December 2023
First Online: 6 January 2024
Competing interests
: J.K.O. serves as a consultant for Medtronic’s valve projects. P.A.F., Z.I.A., E.L., P.A.N., F.L.-J., S.J.A., and J.K.O. have invented algorithms licensed to ANUMANA and may benefit from algorithm commercialization via Mayo Clinic. P.A.F., Z.I.A., F.L.-J., S.J.A., and R.E.C. are members of the scientific advisory board to ANUMANA. B.A.B. receives research support from the National Institutes of Health (NIH) and the United States Department of Defense, as well as research grant funding from AstraZeneca, Axon, GlaxoSmithKline, Medtronic, Mesoblast, Novo Nordisk, Rivus, and Tenax Therapeutics. Dr. Borlaug has served as a consultant for Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations, and is named inventor (US Patent no. 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Other authors declare no competing interests.